PDF
(Download)
|
- Bacopa (Bacopa monnieri)
- Stress
- Mood
|
Date:
08-30-2013 | HC# 081351-479
|
Re: Bacopa Extract Shows Positive, but Minor, Acute Cognition, Mood, and Cortisol Effects
Benson
S, Downey LA, Stough C, Wetherell M, Zangara A, Scholey A. An acute,
double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of
Bacopa monnieri (CDRI 08) on
multitasking stress reactivity and mood. Phytother
Res. 2013; [epub ahead of print].
doi: 10.1002/ptr.5029.
Bacopa
(Bacopa monnieri) has been used for
thousands of years to treat mental disorders. In the 21st century, it
is most commonly used for cognitive enhancement. Preliminary in vivo studies have
demonstrated anxiolytic, antidepressant, sedative, and adaptogenic properties.
The purpose of this double-blind, placebo-controlled, crossover study was to
evaluate 2 acute doses of bacopa for improving cognition, mood, anxiety, and
stress.
Healthy
men (n = 4) and women (n = 13), aged 18-44 years (mean age = 25.23),
participated in this study conducted at Swinburne University, Melbourne, Victoria,
Australia. Subjects were excluded for the following criteria: smoking; a history
of psychiatric disorders or neurological diseases; having endocrine,
gastrointestinal, or bleeding disorders; having chronic illness and infection; pregnancy
or lactation; or taking over-the-counter (OTC) or prescription medications or herbal
extracts. Subjects attended 1 practice visit to become familiar with the
battery of tests, which included the multitasking framework (MTF) cognitive
assessment (mental arithmetic, Stroop [reading colors written in a different
color], letter search, and visual tracking) and mood measures (the Bond-Lader
visual analog scale and the State-Trait Anxiety Inventory [STAI]). Then, they
attended 3 test days, each separated by a 1-week washout period.
The
crossover treatment sequence was computer-randomized to balance the order of
treatment conditions across visits and participants. On each testing day,
participants received either placebo, 320 mg of bacopa (KeenMind® [CDRI
08]; Flordis; St. Leonards, NSW, Australia), or 640 mg of bacopa. CDRI 08 is
standardized to "no less than 55% total bacosides" and is a 25:1
extract prepared with 50% ethanol, made from the stems, leaves, and roots of a
cultured variety of bacopa collected from West Bengal, India. The battery of
MTF tests was taken on each test day at baseline, 1 hour postdose, and 2 hours
postdose. Saliva was collected for cortisol testing and the mood tests were
given both before and after the 1-hour and 2-hour MTF assessments.
There
was no significant difference between treatments in the overall MTF score. When
looking at the subscales, on the Stroop there were significant increases for
all groups at certain timelines compared with their baselines. The letter
search scores were significantly increased compared with baseline for the
bacopa groups. For the letter search score, at 1 hour postdose the change from
baseline with 320 mg of bacopa was significantly greater than the change from
baseline for the placebo group (P = 0.028); the difference between 640 mg of bacopa
and placebo at 2 hours postdose approached significance (P = 0.074). For
subjective mood measures, at 2 hours postdose the change in the alertness score
from baseline with 320 mg of bacopa was significantly greater than the change
from baseline for the placebo group (P = 0.001); the difference between 640 mg of
bacopa and placebo for this time approached significance (P = 0.087). The
ratings for contentedness only approached significance for all times and doses.
There was no significant effect on the calmness rating or STAI scores. At 1
hour and 2 hours postdose, pre-MTF cortisol levels were significantly decreased
with the 640 mg dose compared with the 320 mg dose (P = 0.017 and P = 0.002,
respectively), and with the 640 mg dose compared with placebo (P = 0.18 and P =
0.22, respectively). No significant post-MTF changes were observed.
The
authors conclude that the positive effects suggest that bacopa has an effect at
an earlier time point (1 hour) than previously studied. Also, 2 hours postdose
is the time period when tasks related to reasoning and cognitive speed
improved. Subjective ratings of mood and anxiety were not consistently
improved. The authors state that the changes in cortisol provide a mechanism
for stress reduction. This study is limited by its small population size. None
of the findings are compelling because it was a placebo-controlled study, and
yet the differences between bacopa and placebo were minimal. Perhaps if the
study size had been larger, then more profound statistical differences would
have been observed.
—Heather S. Oliff,
PhD
|